Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + tenofovir disoproxil fumarate
- Development stage
- Phase 4
- Lead developer
- Humax
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtrifovir is a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate, two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). Originally developed by Gilead Sciences under the brand name Truvada, this combination is marketed as a generic in Colombia by Humax and Farmatech (subsidiaries of Bausch Health). It is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, as well as for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk individuals. Both active ingredients work synergistically to inhibit viral reverse transcriptase, thereby blocking viral replication and reducing viral load.
- Brand names
- Emtrifovir
- Other names
- FTC/TDFemtricitabine/tenofovir DFemtricitabine/tenofovir disoproxil fumarate
02
Targets
POLA1 (DNA polymerase alpha)POLB (DNA polymerase beta)POLE (DNA polymerase epsilon)POLG (Mitochondrial DNA polymerase gamma)Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on emtricitabine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil fumarate.